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of the disease P E F R values are steadily low during the 
acute phase submitted to intensive care; then large 
swings appear during the recovery stage, with a 
further decrease in the amplitude of oscillations as the 
patient progressively improves. In such patients wide 
P E F R variations are connected with an increased risk 
of ventilatory arrest [5]: therefore in this condition a 
marked morning dip must be regarded as the 
hallmark of a dangerous airway instability. 
In stable outpatients, the recurrence of some 
morning decrease of P E F R is very common (up to 
9 1 % in our experience), however when a definitely 
high threshold of variation is looked for, a marked 
drop in the prevalence rate (to 15%) is noticed. In 
these patients the amplitude of morning dipping 
seems linked to its frequency, since the deepest falls 
have been reported in subjects in whom the phenome-
non was noticeable on the majority of the monitored 
days [1]. In a similar sample we observed that, 
although morning dipping is initially found in 
subjects with more severe functional picture, it does 
not imply any worse prognosis; in addition, unlike the 
hospitalized patients, where morning dipping may be 
persistent and refractory to therapy, in stable outpati-
ents the pattern may be easily reversible in response to 
treatment or even spontaneously [4]. 
Finally it must be emphasized that the absence of a 
morning dip does not always imply bronchial stability 
and absence of risk: in fact we observed high degrees 
of diurnal variability, even in the presence of 
negligible morning dips (fig. 2). This finding corre-
sponds to the possible, though rare, occurrence of 
patterns of diurnal variation other than the circadian 
one so far discussed. Since exaggerated variability, 
whenever noticed, indicates hyperreactivity, it may be 
recommended that besides the magnitude of morning 
dips, some index of overall variability (such as the 
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Fig. 2. - Relationship between the coefficient of variation (CoV) in 
percent (on the abscissa) and the morning-to-maximum ratio of 
PEFR in percent (on the ordinate). The regression line is 
represented (p<0.01). The points in the right lower quadrant are 
relevant to cases of high variability of PEFR in the absence of a 
significant morning dip. 
coefficient of variation) be included among the output 
of all the programmes of P E F R monitoring. 
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THE PERIPHERAL LYMPHOCYTE AS CLINICAL MODEL FOR 
RECEPTOR DISTURBANCES: ASTHMATIC DISEASES 
E. H a e n * 
In 1968 SZENTIVANYI published a theory relating 
the pathophysiology of asthmatic disorders to recep-
tor disturbances in the sympathetic system [9]. Since 
then much interest had been focused on the cell 
structures that translate external stimuli into intra-
cellular biochemical functions. Two major problems 
had to be solved, however: 
1. A methodology was needed to follow changes at 
the receptor sites. 
2. A clinical model for human lung tissue had to be 
developed, since it is impossible to obtain human lung 
tissue for screening studies, especially if a chronobiol-
ogical design is considered. 
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The methodological development went hand in 
hand with the establishment of the 'Peripheral 
Lymphocyte' as clinical model. These white blood 
cells may be easily and repeatedly collected in large 
numbers without greatly disturbing the patient's 
comfort. Studying insulin receptors on peripheral 
lymphocytes both Archer et al. and Soil et al. 
demonstrated, in 1974, a malfunction of the insulin 
receptor in diabetes. This observation prompted 
studies on other receptor systems. Using a radio-
immunoassay (RIA) C O N O L L Y and G R E E N A C R E [5] 
showed that the cyclic adenosine-monophosphate 
(cAMP) in peripheral lymphocytes of asthmatic 
patients could be stimulated to the same extent as in 
healthy controls, unless the patients were treated with 
p-sympathomimetic drugs. Although this study could 
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not confirm (3-adrenoceptor disturbances in asthma, it 
suggested a biochemical explanation for a clinica 
phenomenon called 'tachyphylaxis', a decreasing 
effectiveness of ^-sympathomimetic drugs under con-
tinuous therapy of asthmatic symptoms. This situa-
tion was obviously caused by either a decreased (3-
adrenoceptor number or a decreased responsiveness 
of the tandem-arranged intracellular biochemical 
events. 
At about the same time radio-receptor-assays 
(RRA) became available, that allowed the determina-
tion of the number of adrenoceptor sites and their 
affinity for certain ligands. In 1976 Williams used 
tritiated dihydroalprenolol in the first R R A for P-
adrenoceptors. With iodinated hydroxy-pindolol 
A A R O N S et al.[\] demonstrated a decrease in receptor 
density under treatment with ^-sympathomimetic 
drugs, a condition that is known today as 'receptor 
down-regulation'. Both mentioned radioligands, 
however, showed a high amount of unspecific 
binding. Therefore, 1 2 5Iodo-cyano-pindolol ( 1 2 5 I -
CYP) is most often used today in p-sympathetic 
RRAs , a radioligand developed by E N G E L et al. [6]. 
In displacement experiments with 1 2 5 I - C Y P 
BRODDE et al. [3] detected a selectivity of the P-
adrenoceptors on peripheral lymphocytes for [32-
ligands and a stereospecificity for their ( - )-forms, in 
other words: The 'Peripheral Lymphocyte' bears P-
adrenoceptors of the same type found primarily on 
bronchial smooth muscle tissue. 
For many years now Professor Remien has used the 
'Peripheral Lymphocyte' as a clinical model for 
hypertensive disorders. Based on the numerous reports 
of circadian variation of asthmatic symptoms (e.g. 
BARNES et al. [2]) we set out to investigate the receptor 
sites in chronic obstructive pulmonary diseases. 
METHODS AND RESULTS 
In a first set of experiments we studied the circadian 
variation of adrenoceptor density in 11 healthy 
subjects (7 males, 4 females, aged 22-34 yr). As 
outlined by P A N G E R L et al. [7], we found a marked 
circadian variation in all subjects with peak values 
around noon and a trough around midnight. This is 
in good agreement with the nocturnal dip reported for 
bronchial patency in asthma. However, we were 
suprised to observe pronounced differences between 
males and females. Nocturnal asthma should be 
found, therefore, more consistently in males, a 
phenomenon not explicitly mentioned in the literature. 
Moreover, for organizational reasons, we had to study 
three of our male subjects in early summer, another 
four in November/December. Despite the small 
number of cases the differences in mesor (1135+10 
sites/cell in summer, 712 ±90 sites/cell in winter) and 
amplitude (17.3 ± 6 . 4 % of mesor in summer, 
34.3 ± 4 . 2 % of mesor in winter) were significant 
(p<0.01 and p<0.05, respectively; X + SE). 
We now investigated asthmatic patients. Like 
Conolly and Greenacre in their c A M P stimulation 
test, S C A R P A C E et al. [8] were unable to detect any 
significant differences between asthmatic and healthy 
people when studying adrenoceptor numbers in 1982. 
Under treatment with a p-sympathomimetic drug, 
however, they observed a down-regulation of 41% in 
their normal subjects. This is in the range reported by 
Aarons, whereas the receptor number decreased to 
undetectable values (0%) in what they called 'asthma-
tic responders'. In our chronobiological investigations 
one patient presented the same reaction to a P-
sympathomimetic dosier aerosol (fig. 1). After one 
week of theophylline treatment his receptor number 
had recovered and showed the known circadian 
variation with a marked nocturnal dip. 
In another patient, who was completely untreated 
at the time of investigation we could demonstrate a 
good correlation between P-adrenoceptor density and 
peak expiratory flow (PEF, r = 0.907), which further 
validates the 'Peripheral Lymphocyte' as clinical 
model for asthmatic diseases. P E F seemed to be 4 h 
phase-delayed to the P-adrenoceptor density (fig. 2), 
the single cosinor method detected a time delay of 71° 
equivalent to 4h44. This patient's circadian variation 
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Fig. 1. - p-adrenoceptor density (Bm a x) on intact peripheral 
lymphocytes in a male asthmatic patient (29 yr) after coninuous 
aerosol therapy with a p-sympathomimetic drug (a) and after one 
week on oral theophylline (b). (From: Langenmayer I, Haen E, 
Emslander H , Remien J: Circadian variation in airway obstruc-
tion. 1986/87, unpublished). 
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Fig. 2. - p-adrenoceptor density (Bm a x) on intact peripheral 
lymphocytes and peak expiratory flow (PEF) in a male asthmatic 
patient (25 yr) who was never treated for asthmatic complaints 
before the time of investigation. Data are expressed as % of the 
24h-mean (24h-mean±SE B m a x : 884 ± 7 8 sites/cell, PEF: 8.4 ± 0 . 4 
1/s). (From: Langenmayer I, Haen E, Emslander H , Remien J: 
Circadian variation in airway obstruction. 1986/87, unpublished) 
of the P-adrenoceptor density fitted well into the 
range observed in our healthy subjects, confirming the 
results of Scarpace and Conolly, but in contrast to 
Szentivanyi's theory. However, taking into account 
the suggested seasonal variation, our patient, who 
was studied in August impressed with a lowered 
mesor (884 compared to 1135 ± 1 0 sites/cell, X + SE) 
and an increased amplitude (26.9% of mesor and a 
range of +25.7/-42.4% of the 24h-mean compared 
to 17.3%) of mesor and a range of + 14.0/- 13.7% of 
the 24h-mean). 
DISCUSSION 
There is a circadian variation of P-adrenoceptor 
density, that may be explained as physiological 
down-regulation by endogenous plasma catecholam-
ine concentrations. The trough in P-adrenoceptor 
density (as determined by P A N G E R L et al. [7]) is about 
6 h phase-delayed to the peak in plasma catecholam-
ine concentrations (as determined by BARNES et al. 
[2]) and in our studies on asthmatics about 4 h 
phase-advanced to the trough in P E F . Nocturnal 
asthmatic complaints might then be regarded as 
hypersensitivity of p2-adrenoceptors to down-regu-
lating stimuli. In healthy people the down-regulated 
P-adrenoceptors do recover due to the increasing 
plasma Cortisol concentrations in the morning. In 
our control group both circadian variations were in 
phase (r = 0.935, p<0.01). Such an up-regulation of 
down-regulated (^-adrenoceptors by glucocorticoids 
was described by B R O D D E et al [4] in a pharmacologi-
cal experiment. 
The clarification of the time relationships between 
the endocrine and receptor variables involved, as well 
as of the seasonal differences in the circadian 
variation of P-adrenoceptor density, will be the most 
important task in the future for uncovering any 
disturbances on the sympathetic receptor level in 
asthma. 
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CONTRIBUTION TO THE CHRONOBIOLOGY OF LUNG FUNCTION: 
CHANGES OF BASELINE VALUES OF FOUR LUNG FUNCTION 
INDICES BETWEEN 8 H AND 17 H IN PATIENTS WITH BRONCHITIC 
COMPLAINTS WITHOUT ASTHMATIC COMPONENTS 
A . M ine t te * 
This contribution deals with the results of a 
longitudinal comparison of forced expiratory volume 
in one second ( F E V 0 , forced expiratory flow when 
25-75% forced vital capacity has been exhaled 
( F E F 2 5 7 5 % F V C ) , peak flow rate (PFR) and residual 
volume (RV) at different hours during the day. The 
study was originally made with a view to studying 
airway-responses to drugs [5] and of epidemiological 
* Medisch Institut St. Barbara, Lanaken. Charge de Cours a 
l'Universite Catholique de Louvain, Bruxelles. 
surveys on respiratory health problems [6]. The 
question was posed as to whether significant biological 
differences exist throughout the day, which would 
necessitate the investigation of all subjects at the same 
hour daily to make valid comparisons. 
The subjects were in-patients with bronchitic 
complains but no asthmatic components. The diagno-
sis was made according to the definitions of the Ciba 
Guest Symposium [l], the symptoms being recorded 
by means of the European Coal and Steel Community 
(ECSC)-questionnaire 1967 [3]. 
